Table 5.

Bacteriologically adverse outcome (either failure or relapse) among patients with high-level fluoroquinolone resistance by initial resistance to drugs included in the shorter treatment regimen.

	Total	Success		Failure		Relapse		pb
	N	N	%	N	%	N	%
	56	34	60.7	16	28.6	6	10.7
KAN								0.7
S	52	32	61.5	14	26.9	6	11.5
R	4	2	50.0	2	50.0	0	0
INH (gDST)								0.5
S	2	2	100	0	0	0	0
R low	3	1	33.3	2	66.7	0	0
R moderate	42	27	64.3	10	23.8	5	11.9
R high	9	4	44.4	4	44.4	1	11.1
INH (pDST)a								0.1
S	0
R low	1	1	100	0	0	0	0
R moderate	34	23	67.6	6	17.6	5	14.7
R high	16	7	43.8	8	50.0	1	6.3
INH (gDST and pDST)a								0.1
S	0
R low	1	1	100	0	0	0	0
R moderate	34	23	67.6	6	17.6	5	14.7
R high	16	7	43.8	8	50.0	1	6.3
EMB								0.7
S	12	9	75.0	2	16.7	1	8.3
R	44	25	56.8	14	31.8	5	11.4
PZA								0.1
S	27	20	74.1	6	22.2	1	3.7
R	29	14	48.3	10	34.5	5	17.2
ETH								0.03
S	42	29	69.0	8	19.0	5	11.9
R	14	5	35.7	8	57.1	1	7.1

EMB, ethambutol; ETH, ethionamide; gDST, genotypic drug susceptibility testing high, high level; INH, isoniazid; KAN, kanamycin; low, low level; moderate, moderate level; pDST, phenotypic drug susceptibility testing; PZA, pyrazinamide; R, resistant; S, susceptible.

^aData on level of phenotypic isoniazid resistance were missing for five patients.

^bFisher's exact test.